PeptiVir
Preventing Viral Disease

Robert S. Hodges, Ph.D. is a Founding Scientist, President and Acting Director of Peptide Chemistry. 


Dr. Hodges is also Professor of Biochemistry and Molecular Genetics and holder of the John Stewart Endowed Chair in Peptide Chemistry at the University of Colorado, School of Medicine.  At the University of Alberta he became a founding member of the Medical Research Council of Canada Group on Protein Structure and Function, Director of the Alberta Peptide Institute and Network Leader of the Protein Engineering Network of Centres of Excellence, a national network.  Dr. Hodges has received many awards among which are the distinguished MRC Scientist Award (considered to be the most prestigious of such awards in Canada), the Boehringer-Mannheim Award from the Canadian Society of Biochemistry and Molecular Biology (in recognition of a record of outstanding achievement in research in the field of Biochemistry), the Vincent du Vignead Award from the American Peptide Society (for outstanding achievements in peptide research) and in 2009 Inventor of the Year award at the University of Colorado Denver.  In addition, he has been President and CEO, member of Boards of Directors, and consultant to biotech companies. His research interests are diverse with over 500 publications and 48 patents/patent applications to his credit.

Kathryn V. Holmes, Ph.D. is a Founding Scientist and Acting Director of Virology.                           

Dr. Holmes is also Professor of Microbiology at the University of Colorado School of Medicine. She earned her PhD from The Rockefeller University and completed postdoctoral research at Harvard University, and had faculty appointments in Georgetown University Schools of Medicine and Dentistry, the University of Texas Southwestern Medical School, and the Uniformed Services University of the Health Sciences before joining the faculty of the Department of Microbiology in the University of Colorado School of Medicine in 1995. Dr. Holmes is an expert on viral envelope glycoproteins and virus receptors. She studies the receptor-induced conformational changes in viral glycoproteins that lead to membrane fusion and virus entry, and analyzes the role of receptor binding specificity on viral host range and evolution. She has published more than 170 papers and book chapters.  Dr. Holmes served as President of the American Society for Virology and as a member of many editorial boards and NIH study sections. She is a Fellow of the AAAS and the American Academy of Microbiology

Richard C. Duke, Ph.D. is the Chairman and Acting CEO.                                                                      

Dr. Duke is a biotechnology executive, inventor, and serial entrepreneur with nearly fifteen years of experience in building, financing, and managing start-up biotechnology companies plus over twenty-five years of experience in biomedical research. Dr. Duke is a Co-Founder and former CEO and President of GlobeImmune and has been involved in the formation of ApopLogic Pharmaceuticals, Sierra Neuropharmaceuticals, Newellink and MenoGeniX. These companies have raised more than $100 million in financing to date and have multiple products in phase 1 and 2 human clinical trials. He is currently President and CEO of the Colorado Institute for Drug Device and Diagnostic Development and is a tenured faculty member in the Univerity fo Colorado Department of Medicine.

Kevin Smith is a Director and Acting CFO.                                                                                            

Mr. Smith is currently COO of the Colorado Institute for Drug Device and Diagnostic Development (CID4). Prior to joining CID4, Kevin was Managing Director of Act Three Consulting, LLC. Act Three was formed in July 2007 to provide consulting services to management teams and their advisors during times of dramatic change. Prior to founding Act Three, Kevin spent nine years as President of Gambro, Inc., the US holding company for the publicly-traded, Swedish-based Gambro Group, until its acquisition by private equity investors in 2006. The US operations of Gambro included the manufacture and distribution of cardiovascular (CV), blood separation and renal dialysis products and the operation of US and international kidney dialysis centers. Before joining Gambro, Kevin was an audit partner in the Denver and New York offices of Ernst & Young, specializing in entrepreneurial services and led the formation of E&Y’s Denver Life Sciences Practice.